Please login to the form below

Not currently logged in
Email:
Password:

Seretide

This page shows the latest Seretide news and features for those working in and with pharma, biotech and healthcare.

Is GSK planning to exit the respiratory business?

Is GSK planning to exit the respiratory business?

Much of its recent success was built on the back of combination therapies that were first introduced in the late 1980s, and culminated in its blockbuster Advair/Seretide (salmeterol/fluticasone propionate)

Latest news

More from news
Approximately 9 fully matching, plus 78 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    Only Seretide/Advair ($8.4bn), Abilify ($8bn) and Crestor ($6.9bn) prevented a biologic clean sweep of the bestsellers. .

  • What can pharma learn from Olympic sports coverage? What can pharma learn from Olympic sports coverage?

    Over the years, the corporation has built a wealth of knowledge in the field, and built and maintained a leading portfolio of respiratory products from Ventolin in 1969 through to Seretide,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics